Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00858572 · ClinicalTrials.gov registry record · Phase 1
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
A Phase 1 study, sponsored by Synta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT00858572: Completed Phase 1 study, sponsored by Synta Pharmaceuticals.
NCT00858572 is a Phase 1 study that has completed, run by Synta Pharmaceuticals. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00858572, a Phase 1 study, has completed, sponsored by Synta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the safety and efficacy of STA-9090 (ganetespib) in subjects with hematologic malignancies.
Interventions
- DRUG STA-9090 (ganetespib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2009-03 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00858572
The ClinicalTrials.gov registry entry for NCT00858572 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Synta Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which STA-9090 (ganetespib) is the first listed.
NCT00858572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00858572 about?
NCT00858572 is a clinical study titled "STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders". The purpose of this study is to characterize the safety and efficacy of STA-9090 (ganetespib) in subjects with hematologic malignancies.
What is the current status of trial NCT00858572?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2009-03. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00858572?
The interventions under investigation include: STA-9090 (ganetespib) (DRUG).
Who is sponsoring clinical trial NCT00858572?
This trial is sponsored by Synta Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.